Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RABGGTB | P53611 | 9/20 | 1.00 |
| ▸ | RABGGTA | Q92696 | 9/20 | 1.00 |
| ▸ | FNTA | P49354 | 1/20 | 0.37 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.34 |
| ▸ | APP | P05067 | 3/20 | 0.33 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10047260 | 1.00 | RABGGTB (1.00) | RABGGTBRABGGTAFNTAPGGT1BPSEN1 | |
| SCHEMBL10073361 | 0.97 | RABGGTB (1.00) | RABGGTBRABGGTAFNTAPGGT1BPSEN1 | |
| SCHEMBL10047259 | 0.97 | RABGGTB (1.00) | RABGGTBRABGGTAFNTAPGGT1BPSEN1 | |
| SCHEMBL10073371 | 0.92 | RABGGTB (0.85) | RABGGTBRABGGTAFNTAPGGT1B | |
| SCHEMBL10047253 | 0.92 | RABGGTB (0.85) | RABGGTBRABGGTAFNTAPGGT1B | |
| SCHEMBL10073370 | 0.87 | RABGGTB (1.00) | RABGGTBRABGGTAPSEN1PSEN2APH1B | |
| SCHEMBL10047265 | 0.87 | RABGGTB (1.00) | RABGGTBRABGGTAPSEN1PSEN2APH1B | |
| SCHEMBL10047250 | 0.86 | RABGGTB (0.83) | RABGGTBRABGGTA | |
| SCHEMBL10073599 | 0.86 | RABGGTB (0.83) | RABGGTBRABGGTA | |
| SCHEMBL10047257 | 0.84 | RABGGTB (0.77) | RABGGTBRABGGTAFNTAPGGT1BPSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093274-B2 | Inhibitors of protein prenyltransferases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100063114-A1 | INHIBITORS OF PROTEIN PRENYLTRANSFERASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063114-A1 | INHIBITORS OF PROTEIN PRENYLTRANSFERASES | GGT1, FNTA, FNTB | RABGGTB 17/4885RABGGTA 5/4885FNTA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.